FDA approves 1st 2-drug HIV treatment combining doravirine and islatravir for adults with suppressed HIV-1, offering a ...
Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
BEAVERTON, OR, UNITED STATES, January 13, 2026 /EINPresswire.com/ — Sedia Biosciences Corporation, a leading developer of innovative diagnostic tests for infectious ...
Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy ...
Hosted on MSN
How Does HIV-2 Differ From HIV-1?
HIV-2 and HIV-1 are both types of human immunodeficiency virus (HIV). They are both transmitted the same way, but HIV-2 does not spread as easily and progresses to AIDS more slowly. Those with HIV-2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results